Adenosine A2A and beta-2 adrenergic receptor agonists: Novel selective and synergistic multiple myeloma targets discovered through systematic combination screening

Molecular Cancer Therapeutics

Volumn 11, Issue 7, 2012, Pages 1432-1442

  Rickles, Richard J ^a   Tam, Winnie F ^a   Giordano III, Thomas P ^a   Pierce, Laura T ^a   Farwell, Melissa ^a   McMillin, Douglas W ^c   Necheva, Antoaneta ^a   Crowe, David ^a   Chen, Mei ^a   Avery, William ^a   Kansra, Vikram ^a   Nawrocki, Steffan T ^b   Carew, Jennifer S ^b   Giles, Francis J ^b   Mitsiades, Constantine S ^c   Borisy, Alexis A ^a   Anderson, Kenneth C ^c   Lee, Margaret S ^a  

^a Zalicus Inc   (United States)

^b CTRC Institute for Drug Development   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; SALMETEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ACTIVITY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MICE; MICE, SCID; MULTIPLE MYELOMA; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863803075     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0925     Document Type: Article

References (41)

1. Gonzalez-Martin AGEICO Group. Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy. Int J Gynecol Cancer 2005;15 Suppl 3:241-6.
2. Nishimura R, Okumura Y, Arima N. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast Cancer 2008;15:57-64.
3. Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program 2007;317-23.
4. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003;100:7977-82. (Pubitemid 36760080)
5. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4:71-8. (Pubitemid 40109591)
6. Alexanian R, Haut A, Khan AU. Treatment for multiple myeloma. JAMA 1969;209:1680-5.
7. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
8. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
9. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6. (Pubitemid 32691956)
10. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2237-80.
11. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 2003;31:271-82. (Pubitemid 36407603)
12. Lehár J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 2007;3:80-94.
13. Lehar J, Krueger A, Zimmermann G, Borisy A. High-order combination effects and biological robustness. Mol Syst Biol 2008;4:215-21.
14. Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotech 2009;7:659-66.
15. Loewe S, Muischnek H. Effect of combinations: mathematical basis of the problem. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1926;114:313-26.
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:22-55.
17. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-85.
18. Zhao L, Au JL, Wientjes MG. Comparison methods for evaluating drug-drug interaction. Front Biosci 2010;2:241-9.
19. Rickles RJ, Pierce LT, Giordano TP III, TamWF,McMillinDW, Delmore J, et al. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood 2010;116:593-602.
20. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10. (Pubitemid 34679544)
21. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010;95:311-9.
22. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-31. (Pubitemid 351969894)
23. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004;5:191-9. (Pubitemid 38283804)
24. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009;23:3649-58.
25. Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25:1182-8.
26. Baughn LB, Liberto MD, Niesvizky R, Cho HJ, Jayabalan D, Lane J, et al. CDK2 phosphorylation of Smad2 disrupts TGF-b transcriptional regulation in resistant primary bone marrow myeloma cells. J Immunol 2009;182:1810-7.
27. Jackson LN, Li J, Chen A, Townsend CM Jr, Evers BM. Overexpression of wild-type PKD2 leads to increased proliferation and invasion of BON endocrine cells. Biochem Biophys Res Commun 2006;348:945-9. (Pubitemid 44233507)
28. Rykx A, Kimpe LD, Mikhalap S, Vantus T, Seufferlein T, Vandenheede JR, et al. Protein kinase D: a family affair. FEBS 2003;546:81-6. (Pubitemid 36782285)
29. Wang WS, Stockwell BR. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol 2008;9:R92.
30. Vlachos P, Nyman U, Hajji N, Joseph B. The cell cycle inhibitor p57 (Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ 2007;14:1497-507. (Pubitemid 47086736)
31. Tong T, Ji J, Jin S, Li X, Fan W, Song Y, et al. Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria. Mol Cell Biol 2005;25:4488-500. (Pubitemid 40705755)
32. Trabosh VA, Divito KA, D Aguda B, Simbulan-Rosenthal CM, Rosenthal DS. Sequestration of E12/E47 and suppression of p27KIP1 play a role in Id2-induced proliferation and tumorigenesis. Carcinogenesis 2009;30:1252-9.
33. Diniz C, Borges F, Santana L, Uriarte E, Oliveira JM, Gonçalves J, et al. Ligands and therapeutic perspectives of adenosine A(2A) receptors. Curr Pharm Des 2008;14:1698-722. (Pubitemid 351998595)
34. Clementina M, Giuseppe S. A2A receptor ligands: past, present and future trends. Curr Top Med Chem 2010;10:902-22.
35. Gemignani AS, Abbott BG. The emerging role of the selective A2A agonist in pharmacologic stress testing. J Nucl Cardiol 2010;17:494-7.
36. Broadley KJ. Beta-adrenoceptor responses of the airways: for better or worse? Eur J Pharmacol 2006;533:15-27. (Pubitemid 43340001)
37. Hancox RJ. Interactions between corticosteroids and beta2-agonists. Clin Rev Allergy Immunol 2006;31:231-46.
38. Black JL, Oliver BG, Roth M. Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting beta-agonists. Chest 2009;136:1095-100.
39. Yasui H, Imai K. Novel molecular-targeted therapeutics for the treatment of cancer. Anticancer Agents Med Chem 2008;8:470-80.
40. Kornek G, Selzer E. Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. Curr Pharm Des 2009;15:207-42.
41. Palazzo A, Iacovelli R, Cortesi E. Past, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets 2010;10:433-61.